Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Mol Oncol.
2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4. Review. PubMed PMID:
34854206; PubMed Central PMCID:
PMC9168966.
A Comparison of (18)F-DCFPyL, (18)F-NaF, and (18)F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer.
J Nucl Med.
2022 May;63(5):735-741. doi: 10.2967/jnumed.121.262371. Epub 2021 Sep 2. PubMed PMID:
34475237.
Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor.
Future Oncol.
2022 Apr;18(11):1333-1342. doi: 10.2217/fon-2021-0930. Epub 2022 Feb 11. PubMed PMID:
35144482; PubMed Central PMCID:
PMC9066292.
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Prostate Cancer Prostatic Dis.
2022 Apr;25(4):735-740. doi: 10.1038/s41391-022-00492-y. Epub 2022 Jan 25. PubMed PMID:
35079115; PubMed Central PMCID:
PMC9309187.
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
J Immunother Cancer.
2022 Jan;10(1). doi: 10.1136/jitc-2021-003392. PubMed PMID:
35017151; PubMed Central PMCID:
PMC8753450.
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Lancet Oncol.
2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9. PubMed PMID:
34895481; PubMed Central PMCID:
PMC8742225.
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
Eur Urol.
2021 Dec;80(6):746-757. doi: 10.1016/j.eururo.2021.03.009. Epub 2021 Mar 27. PubMed PMID:
33785256; PubMed Central PMCID:
PMC8473585.
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations.
Clin Genitourin Cancer.
2021 Dec;19(6):e352-e359. doi: 10.1016/j.clgc.2021.05.005. Epub 2021 May 17. PubMed PMID:
34116956; PubMed Central PMCID:
PMC9595034.
A rare insight into the immunosuppressive landscape of prostate cancer bone metastases.
Cancer Cell.
2021 Nov 8;39(11):1450-1452. doi: 10.1016/j.ccell.2021.09.004. Epub 2021 Nov 8. PubMed PMID:
34752752; PubMed Central PMCID:
PMC9563857.
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
J Immunother Cancer.
2021 Sep;9(9). doi: 10.1136/jitc-2021-003238. PubMed PMID:
34479925; PubMed Central PMCID:
PMC8420671.
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
J Immunother Cancer.
2021 Aug;9(8). doi: 10.1136/jitc-2021-003113. PubMed PMID:
34462327; PubMed Central PMCID:
PMC8407210.
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?.
J Natl Cancer Inst.
2021 Jul 1;113(7):799-800. doi: 10.1093/jnci/djaa217. PubMed PMID:
33432346; PubMed Central PMCID:
PMC8246798.
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
J Immunother Cancer.
2021 Jun;9(6). doi: 10.1136/jitc-2021-002605. PubMed PMID:
34172517; PubMed Central PMCID:
PMC8237736.
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
Oncologist.
2021 May;26(5):e847-e858. doi: 10.1002/onco.13720. Epub 2021 Mar 9. PubMed PMID:
33594772; PubMed Central PMCID:
PMC8100546.
Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans.
IEEE Access.
2021;9:87531-87542. doi: 10.1109/access.2021.3074051. Epub 2021 Apr 20. PubMed PMID:
34733603; PubMed Central PMCID:
PMC8562651.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int.
2021 Apr;127(4):435-444. doi: 10.1111/bju.15227. Epub 2020 Oct 23. PubMed PMID:
32969563; PubMed Central PMCID:
PMC8265825.
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Front Oncol.
2020;10:581801. doi: 10.3389/fonc.2020.581801. eCollection 2020. PubMed PMID:
33747894; PubMed Central PMCID:
PMC7977003.
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Clin Cancer Res.
2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1. PubMed PMID:
33262136; PubMed Central PMCID:
PMC7925349.
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
J Immunother Cancer.
2021 Mar;9(3). doi: 10.1136/jitc-2021-002374. PubMed PMID:
33762322; PubMed Central PMCID:
PMC7993215.
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic.
J Immunother Cancer.
2021 Mar;9(3). doi: 10.1136/jitc-2020-002087. Review. PubMed PMID:
33707314; PubMed Central PMCID:
PMC7956734.
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
J Immunother Cancer.
2021 Mar;9(3). doi: 10.1136/jitc-2020-001556. PubMed PMID:
33664086; PubMed Central PMCID:
PMC7934713.
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
J Immunother Cancer.
2021 Feb;9(2). doi: 10.1136/jitc-2020-002097. PubMed PMID:
33608378; PubMed Central PMCID:
PMC7898875.
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
J Immunother Cancer.
2021 Feb;9(2). doi: 10.1136/jitc-2020-002252. PubMed PMID:
33602697; PubMed Central PMCID:
PMC7896600.
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.
Clin Cancer Res.
2021 Jan 15;27(2):429-437. doi: 10.1158/1078-0432.CCR-20-2344. Epub 2020 Oct 6. PubMed PMID:
33023952; PubMed Central PMCID:
PMC7855232.
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy.
Front Oncol.
2020;10:601452. doi: 10.3389/fonc.2020.601452. eCollection 2020. PubMed PMID:
33520712; PubMed Central PMCID:
PMC7841290.
In Reply.
Oncologist.
2021 Jan;26(1):e192-e193. doi: 10.1002/onco.13589. Epub 2020 Nov 23. PubMed PMID:
33150998; PubMed Central PMCID:
PMC7794181.
Resistance to Immunotherapy: Mechanisms and Means for Overcoming.
Adv Exp Med Biol.
2021;1342:45-80. doi: 10.1007/978-3-030-79308-1_2. PubMed PMID:
34972962.
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
J Immunother Cancer.
2020 Dec;8(2). doi: 10.1136/jitc-2020-001395. PubMed PMID:
33323462; PubMed Central PMCID:
PMC7745517.
Strategies for improving the management of immune-related adverse events.
J Immunother Cancer.
2020 Dec;8(2). doi: 10.1136/jitc-2020-001754. PubMed PMID:
33310772; PubMed Central PMCID:
PMC7735083.
Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report.
Front Oncol.
2020;10:603248. doi: 10.3389/fonc.2020.603248. eCollection 2020. PubMed PMID:
33330104; PubMed Central PMCID:
PMC7717959.
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
J Clin Oncol.
2020 Nov 1;38(31):3672-3684. doi: 10.1200/JCO.20.01652. Epub 2020 Sep 11. PubMed PMID:
32915679; PubMed Central PMCID:
PMC7605393.
Efficacy and immune-related adverse event associations in avelumab-treated patients.
J Immunother Cancer.
2020 Nov;8(2). doi: 10.1136/jitc-2020-001427. PubMed PMID:
33219092; PubMed Central PMCID:
PMC7682456.
The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.
Urol Clin North Am.
2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004. Review. PubMed PMID:
33008496; PubMed Central PMCID:
PMC8177734.
Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management.
J Immunother Cancer.
2020 Nov;8(2). doi: 10.1136/jitc-2020-001019. PubMed PMID:
33219091; PubMed Central PMCID:
PMC7681794.
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
J Immunother Cancer.
2020 Oct;8(2). doi: 10.1136/jitc-2020-001246. PubMed PMID:
33037118; PubMed Central PMCID:
PMC7549450.
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
J Immunother Cancer.
2020 Sep;8(2). doi: 10.1136/jitc-2020-001064. PubMed PMID:
32907924; PubMed Central PMCID:
PMC7481079.
Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation.
JTO Clin Res Rep.
2020 Sep;1(3):100049. doi: 10.1016/j.jtocrr.2020.100049. eCollection 2020 Sep. PubMed PMID:
34589945; PubMed Central PMCID:
PMC8474288.
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Front Endocrinol (Lausanne).
2020;11:490. doi: 10.3389/fendo.2020.00490. eCollection 2020. PubMed PMID:
32849281; PubMed Central PMCID:
PMC7427000.
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Lancet Oncol.
2020 Aug;21(8):1099-1109. doi: 10.1016/S1470-2045(20)30202-3. Epub 2020 Jul 6. PubMed PMID:
32645282; PubMed Central PMCID:
PMC8236112.
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Clin Genitourin Cancer.
2020 Aug;18(4):258-267.e1. doi: 10.1016/j.clgc.2019.11.002. Epub 2020 Mar 29. PubMed PMID:
32327394; PubMed Central PMCID:
PMC7415516.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Elife.
2020 Jul 7;9. doi: 10.7554/eLife.54854. PubMed PMID:
32633234; PubMed Central PMCID:
PMC7340502.
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
J Thorac Oncol.
2020 Jul;15(7):1210-1222. doi: 10.1016/j.jtho.2020.03.003. Epub 2020 Mar 13. PubMed PMID:
32173464; PubMed Central PMCID:
PMC8210474.
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Oncologist.
2020 Jul;25(7):560-e1006. doi: 10.1634/theoncologist.2019-0932. Epub 2019 Dec 26. PubMed PMID:
31876334; PubMed Central PMCID:
PMC7356719.
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
J Immunother Cancer.
2020 Jul;8(2). doi: 10.1136/jitc-2020-000664. PubMed PMID:
32641320; PubMed Central PMCID:
PMC7342865.
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
J Natl Cancer Inst.
2020 Jun 1;112(6):562-573. doi: 10.1093/jnci/djaa021. Review. PubMed PMID:
32145020; PubMed Central PMCID:
PMC7301097.
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Oncologist.
2020 Jun;25(6):479-e899. doi: 10.1634/theoncologist.2019-0608. Epub 2019 Oct 8. PubMed PMID:
31594913; PubMed Central PMCID:
PMC7288633.
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma.
Cancer Gene Ther.
2020 Jun;27(6):438-447. doi: 10.1038/s41417-019-0112-z. Epub 2019 Jun 20. PubMed PMID:
31222182; PubMed Central PMCID:
PMC6923616.
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
J Immunother Cancer.
2020 Apr;8(1). doi: 10.1136/jitc-2020-000878. PubMed PMID:
32300051; PubMed Central PMCID:
PMC7204613.
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Oncologist.
2020 Apr;25(4):290-300. doi: 10.1634/theoncologist.2018-0470. Epub 2019 Oct 10. PubMed PMID:
32297436; PubMed Central PMCID:
PMC7160393.
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
J Nucl Med.
2020 Apr;61(4):552-562. doi: 10.2967/jnumed.119.240929. PubMed PMID:
32238495.
What would you like to do?